



Comment on “Public Spending on Health Service and Policy Research in Canada, the United

Kingdom, and the United States: A Modest Proposal” by Barer, Morris L. & Bryan, Stirling
Health Services Research Spending and Healthcare System 
Impact
Comment on “Public Spending on Health Service and Policy Research in Canada, the United 
Kingdom, and the United States: A Modest Proposal”
Morris L. Barer1*, Stirling Bryan2
Abstract
The challenges associated with translating health services and policy research (HSPR) evidence into practice are 
many and long-standing. Indeed, those challenges have themselves spawned new areas of research, including 
knowledge translation and implementation science. These sub-disciplines have increased our understanding 
of the critical success factors associated with the uptake of research evidence into (system) practice. Engaging 
those for whom research evidence is likely to help solve implementation and/or policy problems, and ensuring 
that they are key partners throughout the research life-cycle, appear to us (based on current evidence) to be 
the most direct and effective paths to improved knowledge translation. In that regard, building on Canada’s 
recent Strategy for Patient Oriented Research (SPOR) would seem to offer considerable promise. The “modest” 
proposals offered by Thakkar and Sullivan seem less likely to bear fruit. 
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The recent paper by Thakkar and Sullivan1 offers a number of interesting insights, and some thoughtful suggestions. Amongst the former, perhaps the most 
striking is the wide disparity across three nations (the United 
States, the United Kingdom, and Canada) in per capita spending 
on healthcare system-related research, and the apparent lack 
of any relationship between that spending, and evidence 
of impact on the quality, effectiveness and efficiency of the 
countries’ respective healthcare systems. Not surprisingly, the 
United States can boast both the most expensive (per capita) 
healthcare system, and the highest per capita spending on 
system-related health research. The country with the lowest 
per capita research spend (UK) appears to have shown the 
most impact of that research spending on healthcare system 
performance. The authors suggest that the latter may be a 
product of the facts that the United Kingdom has a national 
healthcare system, whereas Canada’s is fragmented both by 
geography and sector, and that the United States is a triumph 
of chaos and interests over systematic design and patient 
focus. In fact, the United Kingdom no longer has a single 
healthcare system. Devolution has had real impact in terms of 
healthcare organization and delivery in the United Kingdom 
such that the National Health Service (NHS) in England looks 
and feels quite different to that in Scotland and Wales.2
We were surprised on reviewing the rank order of country 
health services and policy research (HSPR) spend per capita. 
Our prior was that the United Kingdom would be above 
Canada, given the major increases in the United Kingdom. 
health research spend over the last couple of decades. Putting 
aside our skepticism regarding the HSPR spend data, the 
apparent lack of correlation between HSPR research spending 
and system effectiveness or efficiency makes one of the 
authors’ two key recommendations rather perplexing. In 
particular, they suggest that these countries (and presumably 
others) invest a fixed percentage of healthcare spending on 
HSPR, and then earmark that HSPR funding to “effective 
HSPR investments which are instrumental in yielding 
better health outcomes.”1 We see (at least) two fundamental 
problems with this “modest” proposal. The first part of it 
seems logically inconsistent with the authors’ findings of no 
relationship between amounts spent on HSPR and healthcare 
system impact. There is no known evidence-based chain of 
logic that runs from a fixed percent of healthcare spending 
dedicated to HSPR to direct, measurable, and significant 
impacts on a healthcare system’s quality, effectiveness and 
efficiency. The second part appears more troubling still. 
As the authors themselves note, “[t]here is a pressing need 
to track the impact of increased investments in HSPR on 
improvements in health system performance and quality.”1 
But if that is so (and we agree it is), how could one possibly 
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identify which HSPR investments were effective in meeting 
the “better health outcomes” goals prior to making the 
investments and doing the evaluations of impact? 
The problems do not end there. The HSPR literature is littered 
with shining examples of compelling evidence developed 
over long periods of time, pointing to particular policies that 
would, in all likelihood, meet the Triple Aim3 (to improve 
patient experience, population outcomes and affordability). 
Policy progress has not followed. In Canada, the training and 
deployment of nurse practitioners and advanced practice 
nurses,4-6 and the development of a national program 
to cover the costs of prescription medications to reduce 
non-compliance and overall costs7,8 come immediately to 
mind. It seems that in these, and other, areas, additional 
investments in HSPR would be inefficient. Rather, for such 
well-researched HSPR topics, new research investments 
might more productively focus on knowledge translation and 
implementation science, to help us understand and overcome 
the stalling of policy implementation.
Thus, the authors appear to offer a too-narrow understanding 
of the policy-making process (in health as elsewhere), and 
a rather too optimistic view of the importance of research 
evidence in that service. Finally, even if one were somehow able 
to channel that fixed percentage to areas of potential system 
improvement informed by suggestive evaluative evidence, 
there is no guarantee that the evidence will be generalizable or, 
even if it is so theoretically, that it will generalize in practice. 
For example, well-governed and managed institutions tend to 
be high-performing.9,10 But scalability has always been, and is 
likely to continue to be, the challenge.
The authors’ second recommendation, that a concerted 
effort be mounted to move Organisation for Economic Co-
operation and Development (OECD) countries toward 
common nomenclature, indicators and measurement of HSPR 
is, of course, commendable and not something about which 
one would get much argument, from any quarter. But our 
observations of the difficulties of getting to common metrics 
and reporting standards within just one country (Canada) do 
not leave us optimistic about the realistic prospects for such a 
project, at anything beyond the most aggregate of indicators. 
Interprovincial (or even in some cases inter-regional) 
comparative HSPR in Canada continues for the most part to 
be a barren wasteland,11 requiring researchers to deal not only 
with lack of common nomenclature and indicators, but with 
multiple (and often lengthy) data access and ethics approval 
processes – not impossible, but the overhead costs are high. 
While the Canadian Institute for Health Information is well-
positioned to take a leadership role in reducing these sources 
of friction, at the end of the day, success is completely in the 
hands of the individual provinces and territories, which have 
at best a chequered history of working together (in healthcare 
or any other jurisdiction – see, for example, interprovincial 
movement of wine and spirits, or agreement on pipelines). 
Not the least troublesome amongst many impediments to 
progress on this front is that agreeing to the comparability 
project in any arena opens one up to the possibility of being 
found to be below average (since that will, inevitably, be the 
fate of at least some of the jurisdictions). 
As the authors note, despite substantial investments in HSPR 
in all three countries, we remain well short of a system, in any 
of the three countries, that provides comprehensive and timely 
information on the effectiveness and efficiency of HSPR. 
Building on the early work by Buxton,12 important progress is 
being made in refining the process of estimating the return on 
research investment.13 But natural experiments and purpose-
built policy trials are rare, and healthcare systems are messy 
and dynamic, and so generally offer up very low signal to 
noise ratios. 
The authors also note, and we endorse, the promise of the 
recent Canadian-developed “Strategy for Patient-Oriented 
Research” (SPOR). This initiative is designed to improve 
patient care through research that involves not only clinicians 
but also other key stakeholder groups including system 
managers and policy-makers and, importantly, patients 
and their families. It envisions patients being involved in 
identifying research priorities, and being involved throughout 
the research process, including in the application of results 
to changes in how patients experience the healthcare system. 
Patients are viewed as important, for example, to building or 
tweaking metrics for quality of life and helping to identify all 
relevant benefits of clinical interventions or system changes. It 
is still relatively early days for the SPOR initiative, so it is still 
too soon to conclude that it will have the impact on patient 
outcomes that its architects imagined (or at least dreamed of). 
But the recognition that patients have important perspectives 
to offer to the research enterprise and should, after all, be the 
primary focus of all health-related research, is significant and 
long overdue. 
Building on this, and on the fact that the importance of 
embedding knowledge translation and implementation 
science into HSPR is increasingly understood,14 we would 
suggest an alternative, modest and evidence-based proposal. 
One can find many examples of healthcare system-improving 
research in all three countries mentioned by Thakkar and 
Sullivan.15-18 An element common to the vast majority of these 
is the involvement of system decision-makers throughout the 
research life-cycle.19,20 Yet, at least in Canada, and despite 
concerted efforts by the Canadian Institutes of Health 
Research’s (CIHR’s) Institute of HSPR, and the Canadian 
Health Services Research Foundation before it, much of 
HSPR continues to be plagued by two problems. The first 
is that insufficient attention is given to system relevance in 
the research evaluation (peer review) process. As a result, 
even research that is methodologically reasonable and rated 
as of high importance by system managers and/or policy-
makers, is too often left on the cutting room floor, done in 
by hyper-attention to what we would coin pin-head quibbles 
– concerns about methods that are unlikely to have any 
practical impact on results; the best becomes the enemy of 
the potentially practically very useful. The second is that too 
few vehicles for truly engaging system managers and policy-
makers in the research life-cycle (what CIHR refers to as 
“integrated knowledge translation”)21 exist. For example, the 
highly effective CIHR PHSI (Partnerships for Health System 
Improvement) research funding vehicle, which required 
collaboration between research teams and system policy-
makers, was recently discontinued (or rather effectively 
disemboweled) by the funder. 
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This leads to our own modest proposal – that Canada and 
potentially other OECD nations build upon the foundations 
laid by SPOR and expand the Strategy’s current focus on patient 
engagement, to embrace real and effective engagement from 
other key stakeholders, in particular system decision/policy 
makers. Our proposal would imply an HSPR stream within 
SPOR, to ensure a strong voice for those with healthcare 
system management or policy responsibilities, and would 
thus additionally involve policy-makers and system managers 
throughout the process. Importantly, this would include the 
critical preliminary stage of identifying research priorities 
at a more granular level than has been the practice in the 
“Listening for Direction” exercises in Canada. The envisioned 
priorities relating to HSPR would, of course, primarily reflect 
policy-makers’ and managers’ immediate to medium term 
needs for evidence to guide system changes over which they 
have accountability (and the tools to initiate change and 
the funding to evaluate the impacts of change). Once HSPR 
research project or program priorities were identified, those 
involved in setting these priorities would become a critical part 
of the research teams. Complementary activities could include 
helping design system impact metrics that matter to them and 
in particular leading the knowledge translation and exchange 
process. In our view, the most effective way to increase the 
uptake of research evidence in the service of system change is 
to ensure that the research questions are important to those 
with responsibility for system performance. If they have ‘skin 
in the game’ (preferably both funding and incentives to use 
research results), they are more likely to want to be involved 
and to move research results into practice.
We should be under no illusions, however, about the difficulty 
of mapping research results to system change. Research 
evidence accumulates over time, generally requires replication 
to instill confidence, and can often prove fickle – last week’s 
revolutionary finding can turn out to be next week’s old (or 
alternative) news, replaced by newer and more compelling 
evidence. Policy-makers and managers must be cautious 
about embracing HSPR evidence too quickly. This makes the 
task of mapping HSPR evidence to particular system change 
– the elusive search for return on investment (ROI) – an 
ongoing challenge.
In sum, we would simply caution that adopting too-simple 
‘fixes’ such as magic ratios of HSPR investment to system 
expenditures, or trying to impose or extract common metrics 
on wildly divergent systems, may simply end up sending good 
money after bad. 
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